中国药物iza-bren在III期试验中将肺癌生存期延长一倍

本文如何被排名

Signal score

2 / 100

Composite score across the factors below. Higher = stronger signal that this story matters right now.

Newsworthiness bucket

Tool

该集群报道了药物III期临床试验的结果，这构成了一个研究里程碑。[lever_c_demoted from research: ic=1 ai=0.1]

Source corroboration

Single-source cluster

Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.

Topics

paper, product

Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.

AI-industry relevance

Low

Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.

Story freshness

Breaking (< 6h)

Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.

完整方法见我们的编辑标准。